A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for certain types of cancer. These include non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, and esophageal cancer. This study will also help researchers learn how the study medicine moves through and affects the body.
This study is seeking adults who:
- Have advanced non-small cell lung cancer, pancreatic cancer, stomach or gastroesophageal junction cancer, or esophageal cancer.
- Have received at least 1 previous treatment for their cancer.
- Have cancer that has grown, returned, or is no longer responding to available treatments.
All participants in this study will receive PF-08098488 as an IV infusion (given directly into a vein) at the study clinic. Researchers will study different dose levels and dosing schedules to find the dose that is safe and may work best. Participants will be monitored closely during treatment, especially after their first infusion. They may continue receiving the study medicine as long as their cancer is not getting worse and they are tolerating treatment.
The study includes a screening period of up to 28 days. Participants will have regular visits to the study clinic for treatment and health assessments. These assessments include scans to monitor the cancer and blood sample collection. Tumor tissue samples will also be collected when available or medically feasible. After treatment ends, participants will have a follow-up visit about 1 month later. They will then be contacted about every 12 weeks to check on their health.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Rekruttering
- START Midwest, LLC
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- START San Antonio, LLC
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 years of age or older
- Advanced non-small cell lung cancer, pancreatic ductal adenocarcinoma, gastric cancer (including gastroesophageal junction carcinoma), or esophageal cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-1
- Measurable disease
- Must have received at least 1 prior approved systemic therapy:
- Part 1: progression or relapse following standard treatments and have no other appropriate standard of care option.
- Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting.
- Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
- Consent to submit required pre-treatment tumor tissue as medically feasible
Exclusion Criteria:
- Received prior treatment with an antibody drug conjugate with an auristatin or microtubule inhibitor payload.
- Unacceptable renal, hepatic, hematologic, cardiologic, pulmonary, or abnormalities as defined by the protocol.
- Pre-existing sensory or motor neuropathy.
- Uncontrolled diabetes mellitus.
- Clinically significant and/ or symptomatic eye disease meeting protocol exclusion criteria.
- Pulmonary (lung) disease meeting protocol exclusion criteria.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part 1 Dose Escalation
Different groups of participants will receive different doses and/or schedules of the study drug |
IV infusion |
|
Eksperimentel: Part 2 Dose Expansion
Participants in tumor-specific groups will receive 1 dosing regimen deemed to be safe in Part 1 |
IV infusion |
|
Eksperimentel: Part 2 Dose Optimization
Participants will be assigned to one of two dosing regimens deemed to be safe in Part 1 |
IV infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse Events (AEs)
Tidsramme: Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)
|
Number of participants with AEs, characterized by type, frequency, severity, seriousness, and relationship to study intervention during the AE evaluation period. |
Start of study treatment to 30 days after the last dose of study drug administration or start of new anticancer therapy (whichever occurs first)
|
|
Part 1: Recommended Monotherapy Dose(s) for Expansion (RDEM)
Tidsramme: From first dose through completion of Part 1, an average of 1 year
|
From first dose through completion of Part 1, an average of 1 year
|
|
|
Part 2: Recommended Monotherapy Dose for Further Development
Tidsramme: From first dose through completion of Part 2, an average of 2 years
|
From first dose through completion of Part 2, an average of 2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years
|
Percentage of participants with a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator. |
From baseline until first documented disease progression, death, or start of new anticancer therapy, whichever occurs first, up to approximately 3 years
|
|
Duration of Response (DOR)
Tidsramme: From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
|
Time in weeks/months from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. |
From the date of first objective response until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
|
|
Progression Free Survival (PFS)
Tidsramme: From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
|
PFS as defined per RECIST 1.1. |
From first dose until disease progression or death due to any cause, whichever occurs first, up to approximately 3 years
|
|
Overall Survival (OS)
Tidsramme: From first dose until death due to any cause, up to approximately 3 years
|
Time in weeks from the start of study treatment to date of death due to any cause. |
From first dose until death due to any cause, up to approximately 3 years
|
|
Maximum Observed Serum Concentration (Cmax)
Tidsramme: From first dose through End of Treatment (EOT), up to approximately 3 years
|
From first dose through End of Treatment (EOT), up to approximately 3 years
|
|
|
Area under the concentration-time curve (AUC)
Tidsramme: From first dose through End of Treatment (EOT), up to approximately 3 years
|
From first dose through End of Treatment (EOT), up to approximately 3 years
|
|
|
Time to Maximum Observed Serum Concentration (Tmax)
Tidsramme: From first dose through End of Treatment (EOT), up to approximately 3 years
|
From first dose through End of Treatment (EOT), up to approximately 3 years
|
|
|
Number of Participants With Anti-drug Antibody (ADA) against PF-08098488
Tidsramme: Start of study treatment to 30 days after last dose of study drug administration
|
Start of study treatment to 30 days after last dose of study drug administration
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Patologiske processer
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Lungesygdomme
- Neoplasmer i endokrine kirtler
- Neoplasmer i hoved og hals
- Pancreassygdomme
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Neoplastiske processer
- Esophageale sygdomme
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Patologiske tilstande, tegn og symptomer
- Neoplasmer i maven
- Karcinom
- Lungeneoplasmer
- Esophageale neoplasmer
- Neoplasma Metastase
- Bugspytkirtel neoplasmer
- Karcinom, ikke-småcellet lunge
Andre undersøgelses-id-numre
- C6261001
- CEACAM5 EC4V (Anden identifikator: Alias Study Number)
- 2026-527660-32-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .